Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus

Cecilia T Costiniuk; Edward Mills; Curtis L Cooper

doi:10.1155/2008/725702

Canadian Journal of Gastroenterology (Jan 2008)

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus

Cecilia T Costiniuk,
Edward Mills,
Curtis L Cooper

Affiliations

Cecilia T Costiniuk: Department of Internal Medicine, University of Ottawa, Ottawa, Ontario, Canada
Edward Mills: British Columbia Centre of Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada
Curtis L Cooper: University of Ottawa, Division of Infectious Diseases, The Ottawa Hospital — General Campus, Ottawa Health Research Institute, Ottawa, Ontario, Canada

DOI: https://doi.org/10.1155/2008/725702
Journal volume & issue: Vol. 22, no. 4
pp. 376 – 380

Abstract

Read online

OBJECTIVES: The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. Oral cannabinoid-containing medications (OCs) ameliorate chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome. The efficacy of OCs in managing HCV treatment-related side effects is unknown.

Published in Canadian Journal of Gastroenterology

ISSN: 0835-7900 (Print); 1916-7237 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://onlinelibrary.wiley.com/journal/1720

About the journal